Arcutis Biotherapeutics rises on eczema drug launch
22/01/2024 15:10
** Shares of drug maker Arcutis Biotherapeutics ARQT.O
rise 12.3% to $3.65 in early trade
** Co launches its seborrheic dermatitis drug, Zorvye, in
the United States
** Seborrheic dermatitis is a chronic form of eczema that
causes red, itchy skin on the upper back, nose or scalp
** ARQT stock has fallen 77.4% in the last 12 months
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf